Pliant sees Phase IIb as possible pivotal trial of bexotegrast for pulmonary fibrosis

Pliant’s shares gained back little of Monday’s losses suggesting questions about the durability of the company’s idiopathic pulmonary fibrosis therapy continue to outweigh its differentiation from placebo as investors digest the data.

For its part,  Pliant Therapeutics Inc. (NASDAQ:PLRX) maintains that the 24-week data from bexotegrast’s Phase IIa trial show signs of differentiation from other IPF therapies. The company is gearing up to test the strength and durability of the αvβ6 and αvβ1 integrin inhibitor in a 52-week Phase IIb trial slated to start mid-year...